Results 51 to 60 of about 12,405 (251)

Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race

Open Forum Infectious Diseases, 2018
Background This study investigates the association of clinical and demographic predictors with abdominal fat gain, measured using waist circumference (WC) and self-reported abdominal size.
Priya Bhagwat, I. Ofotokun, G. McComsey, T. Brown, C. Moser, Catherine A. Sugar, J. Currier   +6 more
semanticscholar   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.

PLoS ONE, 2014
To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated ...
Joana Cavaco-Silva, Ana Abecasis, Ana Cláudia Miranda, José Poças, Jorge Narciso, Maria João Águas, Fernando Maltez, Isabel Almeida, Isabel Germano, António Diniz, Maria de Fátima Gonçalves, Perpétua Gomes, Celso Cunha, Ricardo Jorge Camacho, Portuguese HIV-2 Resistance Study Group   +14 more
doaj   +1 more source

Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium

Journal of the International AIDS Society, 2020
As integrase inhibitors become available in low‐ and middle‐income countries (LMICs), they offer the potential to expand extremely limited treatment options available to children and adolescents.
G. Patten, T. Puthanakit, C. McGowan, K. Wools-Kaloustian, R. Hazra, J. Pinto, D. Machado, R. Succi, A. Sohn, H. Rabie, B. Musick, M. Davies   +11 more
semanticscholar   +1 more source

Raltegravir In Vitro Effect on Bilirubin Binding [PDF]

Pediatric Infectious Disease Journal, 2013
Drugs that displace bilirubin from albumin may increase the risk of kernicterus in neonates. We evaluated the effect of raltegravir on bilirubin-albumin binding in pooled neonatal serum using the peroxidase method. Raltegravir had minimal effect on bilirubin-albumin binding at concentrations of 5 and 10 µM, caused a small but statistically significant ...
Larissa Wenning, Mark Mirochnick, David K. Stevenson, Diana F Clarke, Ronald J. Wong   +4 more
openaire   +2 more sources

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

The Journal of Clinical Pharmacology, EarlyView.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora, Hui Liu, John Ling, Jason T. Hindman, Dhananjay D. Marathe   +4 more
wiley   +1 more source

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND Dual therapy combining integrase inhibitors and NNRTIs represents a promising regimen in ageing HIV-infected individuals with long exposure to nucleoside analogues and PIs.
C. Katlama, L. Assoumou, M. Valantin, C. Soulie, E. Martinez, L. Béniguel, O. Bouchaud, F. Raffi, J. Molina, S. Fellahi, G. Peytavin, A. Marcelin, S. Kolta, J. Capeau, S. Gibowski, F. Cardon, J. Reynes, D. Costagliola   +17 more
semanticscholar   +1 more source

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV

PLoS ONE, 2020
Objective Optimization of antiretroviral therapy and anti-inflammatory treatments, such as statins, are among the strategies aimed at reducing metabolic disorders, inflammation and immune activation in people living with HIV (PLWH).
E. Negredo, Montse Jiménez, J. Puig, C. Loste, N. Pérez-Álvarez, V. Urrea, P. Echeverría, A. Bonjoch, B. Clotet, J. Blanco   +9 more
semanticscholar   +1 more source

Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment‐experienced people living with HIV: A feasibility survey

HIV Medicine, EarlyView.
Abstract Introduction As life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug–drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART.
Marie Ballif, Manuela Correia da Silva Saúde, David Haerry, Marcel Stoeckle, Patrick Schmid, Dominique Braun, Alexandra Calmy, Gilles Wandeler, Bernard Surial   +8 more
wiley   +1 more source

HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY

Медицинский совет, 2017
The article examines the efficacy and safety of HIV integrase inhibitors (raltegravir, dolutegravir) in antiretroviral therapy (ART) regimens in various groups of HIV-infected patients: patients with high HIV RNA blood levels, patients with low CD4 ...
V. I. SHAKHGILDYAN
doaj   +1 more source